|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003250,
umls-concept:C0020964,
umls-concept:C0025914,
umls-concept:C0026809,
umls-concept:C0030705,
umls-concept:C0038952,
umls-concept:C0086418,
umls-concept:C0205263,
umls-concept:C0233577,
umls-concept:C0913466,
umls-concept:C1321872,
umls-concept:C1537474,
umls-concept:C1979900
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
1992-2-18
|
|
pubmed:abstractText |
Twenty-five patients with stage IV melanoma were immunized with the mouse anti-idiotypic monoclonal antibody (mAb) MK2-23 (2 mg per injection), which bears the internal image of the determinant defined by anti-HMW-MAA mAb 763.74. Two patients were inevaluable, since they did not complete 4 weeks of therapy. Only 14 patients developed antibodies that were shown by serological and immunochemical assays to recognize the same or spatially close determinant as the anti-HMW-MAA mAb 763.74 and to express the idiotope defined by mAb MK2-23 in their antigen-combining sites. Side effects that are likely to be caused by bacillus Calmette-Guérin present in the immunogen consisted of erythema, induration, and ulceration at the sites of the injections. Occasionally, patients complained of flu-like symptoms, arthralgias, and myalgias. Three of the patients who developed anti-HMW-MAA antibodies achieved a partial response. It consisted of a decrease in the size of metastatic lesions and lasted 52 weeks in 1 patient and 93 weeks in the other 2 patients. Survival of the 14 patients who developed anti-HMW-MAA antibodies was significantly (P = 0.0003) longer than that of the 9 patients without detectable humoral anti-HMW-MAA immunity development. In the multivariate analysis, such an association between development of anti-HMW-MAA antibodies and survival prolongation was still significant (P = 0.001) after adjustment for difference in performance status, the only confounding factor found to be significantly related to survival. Lastly, a significant (P = 0.03 by likelihood ratio test) interaction between anti-HMW-MAA antibodies and patients' performance status was found, since the prolongation of survival associated with anti-HMW-MAA antibodies was more marked in patients with a performance status of less than or equal to 70% than in those with a higher one. These results suggest that anti-idiotypic mAb MK2-23 may represent a useful immunogen to implement active specific immunotherapy in patients with melanoma.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/1731316-14097352,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1731316-1671829,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1731316-1716513,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1731316-1861071,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1731316-1933867,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1731316-2254463,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1731316-2430975,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1731316-2450687,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1731316-2584721,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1731316-2689842,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1731316-2784406,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1731316-2824557,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1731316-3289568,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1731316-3472242,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1731316-3591561,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1731316-4793138,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1731316-5432063,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1731316-6252416,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1731316-637870,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1731316-6386801,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1731316-6576184,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1731316-6692408,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1731316-7033148,
http://linkedlifedata.com/resource/pubmed/commentcorrection/1731316-7336169
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0027-8424
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
89
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
466-70
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:1731316-Antibodies, Anti-Idiotypic,
pubmed-meshheading:1731316-Antibodies, Monoclonal,
pubmed-meshheading:1731316-Antibodies, Neoplasm,
pubmed-meshheading:1731316-Antigens, Neoplasm,
pubmed-meshheading:1731316-Female,
pubmed-meshheading:1731316-Humans,
pubmed-meshheading:1731316-Immunization, Passive,
pubmed-meshheading:1731316-Male,
pubmed-meshheading:1731316-Melanoma,
pubmed-meshheading:1731316-Melanoma-Specific Antigens,
pubmed-meshheading:1731316-Middle Aged,
pubmed-meshheading:1731316-Molecular Weight,
pubmed-meshheading:1731316-Neoplasm Proteins,
pubmed-meshheading:1731316-Survival Analysis
|
|
pubmed:year |
1992
|
|
pubmed:articleTitle |
Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma.
|
|
pubmed:affiliation |
Department of Medicine, New York Medical College, Valhalla 10595.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
